Oncternal Therapeutics (ONCT) Insider Trading & Ownership $0.53 0.00 (0.00%) As of 04/29/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.20%Number OfInsiders Buying(Last 3 Years)7Amount OfInsider Buying(Last 3 Years)$149.22KNumber OfInsiders Selling(Last 3 Years)0 Get ONCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ONCT Insider Buying and Selling by Quarter Oncternal Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56 3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72 2/23/2024David F HaleDirectorBuy714$9.04$6,454.56 6/14/2023Gunnar F KaufmannInsiderBuy150$7.20$1,080.00 6/12/2023Gunnar F KaufmannInsiderBuy1,250$7.00$8,750.00 4/14/2023Salim YazjiInsiderBuy250$6.00$1,500.00 4/13/2023James B BreitmeyerCEOBuy5,000$5.80$29,000.00 4/13/2023Richard G VincentCFOBuy1,500$6.00$9,000.00 4/12/2023Chase C LeavittGeneral CounselBuy750$5.80$4,350.00 4/12/2023Salim YazjiInsiderBuy500$5.60$2,800.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) ONCT Insider Trading Activity - Frequently Asked Questions Who is on Oncternal Therapeutics' Insider Roster? The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT. What percentage of Oncternal Therapeutics stock is owned by insiders? 11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings. Which Oncternal Therapeutics insiders have been buying company stock? The following insiders have purchased ONCT shares in the last 24 months: David F Hale ($6,454.56), and Robert James Wills ($86,281.28). How much insider buying is happening at Oncternal Therapeutics? Insiders have purchased a total of 10,714 ONCT shares in the last 24 months for a total of $92,735.84 bought. Oncternal Therapeutics Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Compensation: $881.36kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Compensation: $602.84kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Compensation: $648.53kDr. Rajesh Krishnan Ph.D. (Age 51)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentMs. Anita WisethSenior Vice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies HCWB Insider Trades FRTX Insider Trades ENSC Insider Trades KTTA Insider Trades ATNF Insider Trades GTBP Insider Trades VAXX Insider Trades UBX Insider Trades CNSP Insider Trades THAR Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Do They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield WatchlistInsider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold? This page (NASDAQ:ONCT) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.